Selank
Synthetic analogue of immunomodulatory peptide tuftsin. Studied for anxiolytic effects, cognitive enhancement, and immune modulation without sedation or dependence.
Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is based on a fragment of the immune protein tuftsin and has been studied primarily for anxiolytic (anxiety-reducing) and nootropic effects. What makes it particularly interesting to researchers is the combination it appears to offer: anxiety reduction without the sedation or dependency risk associated with conventional anti-anxiety medications. It is approved and used clinically in Russia for anxiety disorders, giving it more real-world clinical history than most research peptides.
- Russian clinical trials show anxiolytic effects without sedation or dependence.
- Animal studies demonstrate memory enhancement and nootropic effects.
- Immunomodulatory effects observed in preclinical research.
- Approved for use in Russia for anxiety treatment.
- Not evaluated in large independent Western randomized controlled trials.
Selank's evidence base is primarily from Russian research and has not been independently replicated in large Western trials. It is not FDA-approved. The nasal delivery used in clinical studies has variable bioavailability. Some Russian trials compared Selank directly to benzodiazepines using design approaches — such as smaller sample sizes and different outcome measures — that differ from the standards typically required for Western regulatory submissions, which makes direct comparisons harder to interpret. Long-term use effects are not well-characterized.
Selank appears to work primarily through the GABA-A receptor system — the same receptor system that benzodiazepines work through, though at a different binding site and with different downstream effects. Unlike benzodiazepines, Selank does not appear to produce significant sedation or dependence, possibly because it modulates the receptor more selectively. It also appears to influence enkephalin breakdown, preserving naturally occurring anxiety-reducing peptides in the brain for longer. Tuftsin, the protein it is derived from, has immune-signaling properties, and Selank retains some of these while adding the anxiolytic activity through structural modification.
In published Russian clinical trials and clinical use, Selank has been reported as well-tolerated without the sedation, dependence, or withdrawal effects of benzodiazepines. Side effects described are mild. It is not FDA-approved. The independent safety evidence base is limited. Nasal administration carries the standard considerations about mucosal irritation and absorption variability.
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
30 sources · Platform research library · Not generated by AI
Combination use is not endorsed - provided for research context only.
Want More Detailed Research?
Ask the AI anything about Selank - mechanisms, trial summaries, pharmacokinetics, and comparisons.
Ask AI About Selank